Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Bought by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC grew its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 245.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,371 shares of the company's stock after purchasing an additional 5,949 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in Medpace were worth $2,781,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. SBI Securities Co. Ltd. purchased a new stake in shares of Medpace in the 4th quarter valued at approximately $31,000. Jones Financial Companies Lllp grew its holdings in Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after acquiring an additional 110 shares in the last quarter. Lindbrook Capital LLC increased its holdings in Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after buying an additional 29 shares during the last quarter. Assetmark Inc. raised its position in shares of Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after acquiring an additional 29 shares in the last quarter. Finally, Colonial Trust Co SC raised its holdings in Medpace by 150.0% during the fourth quarter. Colonial Trust Co SC now owns 175 shares of the company's stock worth $58,000 after purchasing an additional 105 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on MEDP. Truist Financial reduced their target price on Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a report on Wednesday, April 23rd. Robert W. Baird lowered their target price on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a report on Wednesday, April 23rd. William Blair reaffirmed a "market perform" rating on shares of Medpace in a report on Tuesday, April 22nd. Leerink Partnrs raised shares of Medpace to a "hold" rating in a report on Monday, March 24th. Finally, Leerink Partners began coverage on Medpace in a research note on Monday, March 24th. They set a "market perform" rating and a $330.00 price target on the stock. Eleven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $349.30.

Insiders Place Their Bets

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the business's stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the transaction, the director now owns 2,998 shares in the company, valued at approximately $904,856.36. The trade was a 36.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 20.30% of the stock is owned by insiders.

Medpace Price Performance

MEDP traded up $2.92 on Friday, reaching $296.50. The company's stock had a trading volume of 421,400 shares, compared to its average volume of 358,033. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $459.77. The business's 50 day moving average is $298.09 and its 200 day moving average is $324.07. The stock has a market cap of $8.52 billion, a price-to-earnings ratio of 23.48, a price-to-earnings-growth ratio of 3.81 and a beta of 1.55.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. Medpace had a return on equity of 51.48% and a net margin of 19.17%. The business had revenue of $558.57 million during the quarter, compared to the consensus estimate of $528.38 million. During the same period last year, the firm earned $3.20 earnings per share. As a group, research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.